Cryptococcosis due to Cryptococcus gattii

Clinical Infectious Diseases

Volumn 57, Issue 4, 2013, Pages 552-554

  Rolston, Kenneth V I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cryptococcus gattii; Immunocompetent hosts; Treatment

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ISAVUCONAZOLE; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; CELLULAR IMMUNITY; CENTRAL NERVOUS SYSTEM; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; DISEASE PREDISPOSITION; EPIDEMIC; FOLLOW UP; FUNGAL STRAIN; HUMAN; IMMUNOCOMPROMISED PATIENT; INFLAMMATION; MINIMUM INHIBITORY CONCENTRATION; NOTE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT DURATION;

CRYPTOCOCCUS GATTII; IMMUNOCOMPETENT HOSTS; TREATMENT;

ANTIFUNGAL AGENTS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; FEMALE; HUMANS; MALE;

EID: 84880954681     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit342     Document Type: Note

References (21)

1. La Hoz RM, Pappas PG. Cryptococcal infections: changing epidemiology and implications for therapy. Drugs 2013; 73: 495-504.
2. Baddley JW, Dismukes WE. Cryptococcosis. In: Kauffman CA, Pappas PG, Sobel JD, Dismukers WE, eds. Essentials of clinical mycology. 2nd ed. New York: Springer, 2011:207-26.
3. Chen J, Varma A, Diaz MR, Litvintseva AP, Wollenberg KK, Kwon-Chung KJ. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg Infect Dis 2008; 14:755-62.
4. Choi YH, Ngamskulrungroj P, Varma A, et al. Prevalence of the VNIc genotype of Cryptococcus neoformans in non-HI Vassociated cryptococcosis in the Republic of Korea. FEMS Yeast Res 2010; 10:769-78.
5. Ellis DH, Pfeiffer TJ. Natural habitat of Cryptococcus neoformans var. gattii. J Clin Microbiol 1990; 28:1642-4.
6. Harris JR, Lockhart SR, Debess E, et al. Cryptococcus gattii in the United States: clinical aspects of infection with an emerging pathogen. Clin Infect Dis 2011; 53:1188-95.
7. Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291-322.
8. Chen SC, Slavin MA, Heath CH, et al. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin Infect Dis 2012; 55: 789-98.
9. Perfect JR. The triple threat of cryptococcosis: it's the body site, the strain, and/or the host. MBio 2012; 3.
10. Marr KA. Cryptococcus gattii: the tip of the iceberg. Clin Infect Dis 2011; 53:1196-8.
11. Feng X, Fu X, Ling B, Wang L, Liao W, Yao Z. Development of a singleplex PCR assay for rapid identification and differentiation of Cryptococcus neoformans var. grubii, Cryptococcus neoformans var. neoformans, Cryptococcus gattii and hybrids. J Clin Microbiol 2013; 51:1920-3.
12. Lockhart SR, Iqbal N, Bolden CB, et al. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn Microbiol Infect Dis 2012; 73:144-8.
13. Brummer E, Kamei K, Miyaji M. Anticryptococcal activity of voriconazole against Cryptococcus neoformans var. gatti vs var. neoformans: comparison with fluconazole and effect of human serum. Mycopathologia 1998; 142:3-7.
14. Hagen F, Illnait-Zaragozi MT, Bartlett KH, et al. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob Agents Chemother 2010; 54:5139-45.
15. Santos JR, Gouveia LF, Taylor EL, et al. Dynamic interaction between fluconazole and amphotericin B against Cryptococcus gattii. Antimicrob Agents Chemother 2012; 56:2553-8.
16. Magalhaes TF, da Silva CM, de Fatima A, et al. Hydroxyaldimines as potent in vitro anticryptococcal agents [published online ahead of print 18 April 2013]. Lett Appl Microbiol 2013; doi:10.1111/lam.12086.
17. Schoffelen T, Illnait-Zaragozi MT, Joosten LA, et al. Cryptococcus gattii induces a cytokine pattern that is distinct from other cryptococcal species. PLoS One 2013; 8:e55579.
18. Mershon KL, Vasuthasawat A, Lawson GW, Morrison SL, Beenhouwer DO. Role of complement in protection against Cryptococcus gattii infection. Infect Immun 2009; 77:1061-70.
19. Marr KA, Datta K, Pirofski LA, Barnes R. Cryptococcus gattii infection in healthy hosts: a sentinel for subclinical immunodeficiency? Clin Infect Dis 2012; 54:153-4.
20. Chaturvedi V, Nierman WC. Cryptococcus gattii comparative genomics and transcriptomics: a NIH/NIAID white paper. Mycopathologia 2012; 173:367-73.
21. Kidd SE, Bach PJ, Hingston AO, et al. Cryptococcus gattii dispersal mechanisms, British Columbia, Canada. Emerg Infect Dis 2007; 13:51-7.